1. Home
  2. NGNE vs AREC Comparison

NGNE vs AREC Comparison

Compare NGNE & AREC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$21.31

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo American Resources Corporation

AREC

American Resources Corporation

HOLD

Current Price

$2.63

Market Cap

376.4M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
AREC
Founded
2003
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Coal Mining
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
376.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NGNE
AREC
Price
$21.31
$2.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
4
Target Price
$38.50
$5.67
AVG Volume (30 Days)
226.2K
5.6M
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$95,026.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$52,633.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$0.38
52 Week High
$37.27
$7.11

Technical Indicators

Market Signals
Indicator
NGNE
AREC
Relative Strength Index (RSI) 44.24 41.93
Support Level $19.65 $2.50
Resistance Level $23.00 $3.25
Average True Range (ATR) 1.44 0.25
MACD 0.27 -0.00
Stochastic Oscillator 50.79 18.12

Price Performance

Historical Comparison
NGNE
AREC

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About AREC American Resources Corporation

American Resources Corp constructs and/or purchases and manages a chain of combined gasoline, diesel and natural gas (NG) fueling and service stations; construct conversion factories to convert NG to liquefied natural gas (LNG) and compressed natural gas (CNG); and construct conversion factories to retrofit vehicles currently using gasoline or diesel fuel to also run on NG in the United States and also to build a convenience store to serve its customers in each of its locations. Its segments are AIC focused on the extraction, processing, transportation, and distribution of coal for a variety of industries, with a focus on metallurgical quality coal to the steel industry; RLMT; and EMC.

Share on Social Networks: